Semaglutide linked to significant reduction in asthma and COPD attacks

New research presented at the European Respiratory Society Congress suggests that GLP-1 receptor agonists, such as semaglutide, may offer significant respiratory benefits. A study led by Imperial College London using UK medical records found that semaglutide was associated with a nearly 40% reduction in asthma attacks and a 20% reduction in COPD flare-ups. While these findings are encouraging, researchers emphasize that they are observational and require further clinical trials before changing medical guidelines.

Beyond respiratory health, studies indicate broader systemic effects. Research from Griffith University suggests semaglutide may be linked to a 21% lower risk of psychiatric hospitalization in individuals with bipolar disorder. Additionally, observations indicate that these medications may reduce cravings for alcohol and nicotine.

In Brazil, the regulatory agency Anvisa has approved the entry of generic liraglutide medications produced by EMS, which is expected to increase market competition and lower costs. However, medical professionals warn that rapid weight loss from these drugs can lead to side effects such as muscle mass loss and skin sagging, necessitating nutritional guidance and physical activity to maintain health.